Get started
Author

Anna Łojko‐Dankowska

Observed names: A. Lojko‐Dankowska, ANNA ŁOJKO-DANKOWSKA, Anna Lojko-Dankowska, Anna Lojko–Dankowska, Anna Łojko-Dankowska, Anna Łojko–Dankowska, Łojko-Dankowska A
ORCID: 0000-0003-0209-3282
Observed ORCID: 0000-0003-0209-3282
OpenAlex ID: A5022372342
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
2023 · Dominik Dytfeld, Tomasz Wróbel, et al. · The Lancet Oncology · 81
PDF
Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
2024 · Tadeusz Kubicki, Dominik Dytfeld, et al. · Blood · 35
PDF
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience
2013 · Anna Czyz, Anna Lojko-Dankowska, et al. · Medical Oncology · 21
PDF
Safety and cost effectiveness of outpatient autologous hematopoietic stem cell transplantation for multiple myeloma — single-center experience of a pilot Early Discharge Program
2021 · Dominik Dytfeld, Anna Łojko-Dankowska, et al. · Acta Haematologica Polonica · 14
PDF
CAR-T cell therapy – toxicity and its management
2020 · Lidia Gil, Anna Łojko-Dankowska, et al. · Acta Haematologica Polonica · 14
Depression and anxiety in patients recently recovered from coronavirus disease (COVID‑19)
2021 · Rafał Dankowski, Wioletta Sacharczuk, et al. · Neuropsychiatria i Neuropsychologia · 13
PDF
HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor
2018 · Jacek Nowak, Klaudia Nestorowicz, et al. · Human Immunology · 13
Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis
2013 · Anna Czyz, Joanna Romejko-Jarosinska, et al. · Annals of Hematology · 11
PDF
Road to clinical implementation of CAR-T technology in Poznań
2020 · Dominik Dytfeld, Anna Łojko-Dankowska, et al. · Acta Haematologica Polonica · 7
Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma – characteristics and risk factors analysis
2013 · Anna Czyż, Anna Łojko-Dankowska, et al. · Współczesna Onkologia · 7
PDF
Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity
2021 · Rafał Dankowski, Wioletta Sacharczuk, et al. · Kardiologia Polska · 6
PDF
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant
2012 · Anna Czyz, Joanna Romejko-Jarosinska, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
2023 · Tadeusz Kubicki, Dominik Dytfeld, et al. · Blood · 5
Clinical outcomes of therapy-related acute myeloid leukemia: over 20 years long single center retrospective analysis
2022 · Monika Adamska, Ewelina Kowal-Wiśniewska, et al. · Polskie Archiwum Medycyny Wewnętrznej · 5
PDF
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM).
2025 · Andrzej J. Jakubowiak, Tomasz Wrobel, et al. · Journal of Clinical Oncology · 4
Should we Cryopreserve Allogenic Hematopoietic Stem Cell Grafts?
2025 · EWA BEMBNISTA, PATRYCJA STAWICKA, et al. · In Vivo · 3
Acute Myeloid Leukemia Post Cytotoxic Therapy in Breast Cancer Survivors—Over 23 Years of Single Center Analysis
2024 · Monika Adamska, Ewelina Kowal-Wiśniewska, et al. · Journal of Clinical Medicine · 3
PDF
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
2023 · Tadeusz Kubicki, Dominik Dytfeld, et al. · British Journal of Haematology · 3
PDF
Neutropenic enterocolitis and multidrug-resistant bacteria colonization in lymphoma patients undergoing autologous stem cell transplantation
2022 · Monika Joks, Joanna Rupa-Matysek, et al. · Acta Haematologica Polonica · 3
PDF
ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
2022 · Dominik Dytfeld, Tomasz Wrobel, et al. · Journal of Clinical Oncology · 3
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
2026 · Dominik Dytfeld, Tomasz Wróbel, et al. · The Lancet Haematology · 2
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized Phase III COBRA trial.
2025 · Dominik Dytfeld, Tadeusz Kubicki, et al. · Blood · 2
PDF
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone
2024 · Tadeusz Kubicki, Krzysztof Jamroziak, et al. · Polskie Archiwum Medycyny Wewnętrznej · 2
Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial
2023 · Tadeusz Kubicki, Dominik Dytfeld, et al. · Blood · 2
Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group
2019 · Anna Czyz, Anna Lojko-Dankowska, et al. · Blood · 2
Works count: 53
Citation count: 275
H-index: 8
I10-index: 8
Year
Topic
Type